Shots:
- BMS & BioNTech will co-develop & co-commercialize BioNTech’s BNT327 alone & in combination to treat solid tumors; BMS to hold MA globally excl. the US, UK, China, Turkey, & EU, where BioNTech will be the holder
- As per the deal, BioNTech will receive $1.5B upfront, $2B in non-contingent annual payments through 2028 & ~$7.6B in additional development, regulatory & commercial milestones. Both companies will equally share joint development & manufacturing costs, with certain exceptions along with global profits/losses, while retaining rights to independently develop BNT327 for further indications
- BNT327 is being assessed in ongoing P-III trials for 1L ES-SCLC & NSCLC; a P-III trial for TNBC is planned to start by 2025 end
Ref: BMS & BioNTech | Image: BMS &BioNTech| Press Release
Related News:- BMS’ Opdivo Receives the EC’s Approval as a Perioperative Treatment of Resectable NSCLC
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
